Isofol Medical AB (FRA:5IU)
€ 0.0474 -0.0037 (-7.24%) Market Cap: 9.86 Mil Enterprise Value: -2.54 Mil PE Ratio: 0 PB Ratio: 1.11 GF Score: 31/100

Q2 2022 Isofol Medical AB (publ) Earnings Call Transcript

Aug 23, 2022 / 10:30AM GMT
Release Date Price: €0.1144 (+2.14%)
Ulf Jungnelius;publ;CEO
Isofol Medical AB

()-

Thank you so much. And let's change slide to slide number 4.

So we are presenting the second-quarter results. Keep in mind then that we had a press release couple of weeks ago detailing our study results, the topline results showing that we did not achieve our endpoints. So if we take a look at the company at a glance, it was founded in Gothenburg 40 years ago. We have a strong financial position. We are listed on Nasdaq Stockholm.

We have been developing [Avastin drug] arfolitixorin for the treatment of colorectal cancer. We have a small experienced team in Gothenburg, and we've been very pragmatically working with work orders being data driven. And our vision was to contribute to extending lives and improving quality of life for the poor people suffering from metastatic colorectal cancer, a disease with a remaining still high unmet medical need.

If we go to the next slide on page 5, this is a little bit of depiction of the Phase III study, the AGENT study. We have the control arm being modified

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot